semaglutide and cardiovascular outcomes in diabetes Part 5 of landmark studies about Do you want more? #ebm #dm #research Cardiovascular risk reduction with once-weekly

Tiredness may result from reduced calorie intake, rapid weight loss, dehydration, or dose increases

Comorbidities included chronic kidney disease (34.54%), diabetes (38.34%), and hypertension (97.6%)

You administer the medication yourself by injecting the small needle into fatty tissue underneath your skin

As of 2021, semaglutide also has been approved for weight loss

But following clinical trial results, liraglutide sold under the name Saxenda, gained approval in 2017 as a weight loss medication for people with a BMI of 30 or higher or for people with a BMI of 27 and higher who also have a metabolic health condition

That's super important